Publications:101
Evren U Azeloglu, PhD
About Me
Dr. Azeloglu is a Professor of Medicine in the Division of Nephrology with a secondary appointment in the Department of Pharmacological Sciences. He is a member of the Center for Engineering and Precision Medicine and Black Family Stem Cell Institute. He received his B.E. in Mechanical Engineering and M.S. in Biomedical Engineering from State University of New York at Stony Brook. He completed his Ph.D. in Biomedical Engineering from Columbia University in the City of New York and a postdoctoral fellowship in Department of Pharmacology and Systems Therapeutics in Icahn School of Medicine at Mount Sinai. Dr. Azeloglu was awarded the Yuen-huo Hung & Chao-chin Huang Award from Columbia University, Howard Hughes Medical Institute fellowship from the Life Science Research Foundation, Career Development Award from the American Society of Nephrology, and i3 Innovation Award from Mount Sinai. Funded by numerous extramural grants, his Systems Bioengineering Lab aims to harness mechanobiological principles to deepen our understanding of fundamental cell physiology and develop new precision medicine technologies.
Language
English
Position
PROFESSOR | Medicine, Nephrology, PROFESSOR | Artificial Intelligence and Human Health, PROFESSOR | Pharmacological Sciences
Research Topics
Biomechanics/Bioengineering, Biophysics, Cardiovascular, Cell Adhesion, Computational Biology, Cytoskeleton, Kidney, Mathematical Modeling of Biomedical Systems, Mathematical and Computational Biology, Nanotechnology, Signal Transduction, Stem Cells, Systems Biology, Systems Pharmacology, Tissue Engineering, Translational Research
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Development Regeneration and Stem Cells [DRS], Disease Mechanisms and Therapeutics (DMT)
Education
B.E., Stony Brook University
M.S., Stony Brook University
Ph.D., Columbia University
Awards
2015
NephCure Kidney International ASN Foundation Kidney Research Award
American Society of Nephrology
2010
Howard Hughes Medical Institute Fellowship
Life Science Research Foundation
2005
Stony Wold Herbert Fellowship
2004
Yuen-huo Hung & Chao-chin Huang Award (2009)
Columbia University
Research
Our main goal at the Systems Bioengineering Lab is to understand mechanobiological decision-making capabilities and to develop novel therapeutics for precision medicine. We employ multiscale experimental and computational techniques as well as microfabrication and tissue engineering methods to study cell signaling, biomechanics, tissue function and regeneration using human induced pluripotent stem cell-derived cardiovascular and renal model systems. We also use multi-platform omics technologies and network analyses for identification of key information processing hubs and regulatory motifs that can be used as therapeutic targets in drug development for complex diseases such as hypertension, diabetic nephropathy and heart failure. See Azeloglu Lab website for more details.
Publications
Selected Publications
- Kidney organoids as a platform to study plasminogen-induced injury and uPA-based therapies. Marina de Cos, Samuel Mon Wei Yu, Jacob Wright, Nanditha Anandakrishnan, Kristin Meliambro, Jenny S. Wong, Evren Azeloglu, Kirk N. Campbell. Stem Cells Translational Medicine
- Podocyte-derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis. Liping Yu, Ubong S. Ekperikpe, Hunter W. Korsmo, Serena Zhao, Zhengzi Yi, Jonathan Haydak, Sean Lefferts, Kristin Meliambro, Kirk N. Campbell, Evren U. Azeloglu, Donald E. Kohan, Phillip J. McCown, Abhijit S. Naik, Edgar A. Otto, Börje Haraldsson, Weijia Zhang, Ilse S. Daehn. Kidney International
- Kidney-on-Chip and Organoid Models: Harnessing Mechanical Forces for Translational Kidney Biology. Abigail Daily, Nanditha Anandakrishnan, Jonathan Haydak, Jonathan Himmelfarb, Evren U. Azeloglu. Journal of the American Society of Nephrology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Azeloglu during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Board Service
- Flowpoint Medical Inc.
Consulting or Other Professional Services
Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership- Orion Corporation
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- Flowpoint Medical Inc.
Founder/Co-Founder/Partner
- Flowpoint Medical Inc.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.